Crossmark Global Holdings’s Bicycle Therapeutics BCYC Stock Holding History

Crossmark Global Holdings’s Portfolio BCYC Stock Details BCYC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$48.3K	Sell	11,402 -6	-0.1%	-$28	﹤0.01%	1259
2026 Q1	$52.9K	Buy	11,408 +9	+0.1%	+$51	﹤0.01%	1232
2025 Q4	$80.7K	Buy	11,399 +9	+0.1%	+$66	﹤0.01%	1215
2025 Q3	$88.2K	Buy	11,390 +1	+0%	+$8	﹤0.01%	1279
2025 Q2	$79.2K	Sell	11,389 -11	-0.1%	-$88	﹤0.01%	1314
2025 Q1	$96.8K	Buy	11,400 +22	+0.2%	+$259	﹤0.01%	1304
2024 Q4	$159K	Buy	11,378 +11	+0.1%	+$236	﹤0.01%	1230
2024 Q3	$257K	Buy	+11,367	New	+$262K	﹤0.01%	1142

Other funds holding BCYC

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

GSK plc London $602M AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Crossmark Global Holdings's BCYC Position: Q2 2026 in Review

Crossmark Global Holdings reduced its Bicycle Therapeutics (BCYC) stake by 0.05% in Q2 2026, selling an estimated $28 and leaving 11,402 shares worth $48.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1259.

Crossmark Global Holdings first reported a position in BCYC in Q3 2024 and has held it in 8 quarters since. The position peaked at $257K in Q3 2024. 104 funds tracked by Wall St. Rank hold BCYC as of Q2 2026.

Crossmark Global Holdings held 11,402 shares of Bicycle Therapeutics worth $48.3K as of Q2 2026.
Crossmark Global Holdings sold 6 Bicycle Therapeutics shares in Q2 2026, an estimated $28.
Bicycle Therapeutics made up ﹤0.01% of Crossmark Global Holdings's portfolio in Q2 2026, its #1259 holding.
Crossmark Global Holdings first reported a position in Bicycle Therapeutics in Q3 2024 and has held it in 8 quarters since.
Crossmark Global Holdings's Bicycle Therapeutics position peaked at $257K in Q3 2024.
104 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q2 2026.

Based on Crossmark Global Holdings's 13F filing for Q2 2026, filed 16 Jul 2026.